Scrip
Top-line success for AstraZeneca's Brilinta
11 May 2009
Alex Shimmings
AstraZeneca's investigational oral antiplatelet therapy ticagrelor (Brilinta) has met the primary endpoint in a Phase III study comparing it with clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis's (Plavix), the company has announced. The study was designed to see whether ticagrelor is better than clopidogrel...
Please Login to read the full article.
11 May 2009
Alex Shimmings
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Anti-obesity drugs: an inventor's perspective
- Face-to-face with Abingworth's Stephen Bunting:we've had time to adapt to tough markets
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
